AlphAIAlphAI — Financial news for AI agents
seekingalpha.comOCT 301 min read$KVUE

Kenvue Non-GAAP EPS of $0.29 in-line, revenue of $3.89B beats by $30M (KVUE:NYSE)

Kenvue (KVUE) reported Q3 Non-GAAP EPS of $0.29, meeting estimates, and revenue of $3.89B, exceeding expectations by $30M. Year-over-year revenue growth was 3.5%, driven by organic sales growth and foreign currency benefits.

Original reporting
seekingalpha.com
Published Oct 30, 2026, 10:48 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 30, 2026, 10:53 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefEarnings
Primary signal
$KVUE
Bullish
high confidence
Mentioned
$KVUE
Relevance
8/10
AlphAI data visualization · based on seekingalpha.com
Decision brief

The 30-second read

$KVUEBullishMed
01

Why it matters

The modest revenue beat could provide short‑term support, while EPS in‑line may limit rally.

02

Market read

First report of earnings; provides fresh data for traders.

03

What to watch

Foreign‑currency benefit contributed to sales; any reversal could pressure results.

Relevance 8/10Novelty 8/10Timing: post‑market today

Background

Kenvue, a consumer health products company, released its Q3 2026 earnings via press release.

Company-level read

Ticker impact

$KVUEBullishHigh confidence
Context

Q3 2026 Non-GAAP EPS in-line at $0.29 and revenue $3.89B beating estimates by $30M.

Expected impact

modest upside as market prices in revenue beat

Evidence & confidence

Revenue beat suggests growth momentum; EPS in‑line reduces risk of downside.

Market effects

Sector

Consumer health sector may see slight lift from Kenvue's revenue beat.

Regional

U.S. market may experience modest positive bias in consumer staples.

Global

Limited; primarily U.S. investors focused on earnings.

Counterpoint

What could challenge this read

Revenue beat may be offset by in‑line EPS, suggesting limited upside.

Key entities

  • Company
    Kenvue

    Consumer health products maker, ticker KVUE.

Read at source← All news

StoryKenvue posts Q3 2026 earnings amid pending Kimberly‑Clark merger

Also covered by

4 outlets

Related articles

OCT 30
$OKTAHighAI 8/10

Okta to Replace Kenvue in S&P 500 Amid Kimberly-Clark Acquisition

S&P Dow Jones Indices announced Okta (OKTA) will replace Kenvue (KVUE) in the S&P 500 on November 4, 2026, due to Kenvue's acquisition by Kimberly-Clark (KMB). Kenvue's valuation is $48.7B, with a $21.01 per-share consideration. Glaukos (GKOS) will replace Okta in the S&P MidCap 400, and McGrath RentCorp (MGRC) will replace Glaukos in the S&P SmallCap 600. Loar Holdings (LOAR) will replace LiveRamp (RAMP) in the S&P SmallCap 600 due to LiveRamp's acquisition by Publicis Groupe (PU4.DE).

securities.io3 min
OCT 30
$KVUEMedAI 8/10

Kenvue Q3 2026: Sales Up 3.2% to $3.89B, Adjusted EPS $0.29, No Guidance on Kimberly-Clark Deal

Kenvue Inc. (NYSE: KVUE) reported Q3 2026 net sales of $3.89B, up 3.2% YoY, with adjusted EPS of $0.29. Gross and operating margins improved, driven by supply-chain savings and tariff refunds. Self Care and Essential Health segments grew, while Skin Health and Beauty lagged. Free cash flow rose to $1.6B. No guidance was provided due to the pending Kimberly-Clark deal.

minichart.com.sg2 min
OCT 30
$KVUEHighAI 8/10

Kenvue posts higher profit, fourth straight sales gain in Q3 earnings

Kenvue reported Q3 adjusted earnings per share of 29 cents, up from 28 cents, and organic sales growth of 2.9%. Revenue exceeded $3.86 billion, matching analyst estimates. Self Care net sales rose 5.9%, while Skin Health and Beauty saw a slight decline. Gross and operating margins improved, and free cash flow increased. CEO Kirk Perry noted progress in operational overhaul and the pending combination with Kimberly-Clark.

qz.com2 min
OCT 30
$KVUEMed

Kenvue Delivers Fourth Consecutive Quarter of Sales Growth

Kenvue reported Q3 2026 net sales growth of 3.2% and organic sales growth of 2.9%, marking four consecutive quarters of sales growth. CEO Kirk Perry attributed the performance to strong execution, productivity initiatives, and brand investments. Skin Health & Beauty sales declined slightly, while Hair Care saw double-digit growth. Self Care segment increased by 5.9%. The company is on track for its business transformation and upcoming combination with Kimberly-Clark.

beautypackaging.com2 min
OCT 30
$KVUEHighAI 9/10

Kenvue Q3 Sales Rise 3.2% as EPS Increases 5%

Kenvue reported Q3 2026 net sales growth of 3.2% to $4.1B, with EPS up 5% to $0.22. Organic sales rose 2.9%, driven by volume growth and value realization. Gross and operating margins improved, while cash flow increased. The company did not provide guidance due to its pending merger with Kimberly-Clark.

grafa.com2 min